Gilead Sciences Executives
- All
- News
-
How an $84,000 Drug Got Its Price: 'Let's Hold our Position... Whatever the Headlines'
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
-
ITC's Deveshwar, 7 other Indians in Harvard Business Review's list of top 100 CEOs
Eight Indian CEOs have made it to the list of 100 global chief executives, compiled by Harvard Business Review (HBR), with ITC's Y C Deveshwar and late Subir Raha of ONGC finding a place in the top 20.
-
How an $84,000 Drug Got Its Price: 'Let's Hold our Position... Whatever the Headlines'
Gilead Sciences executives were acutely aware in 2013 that their plan to charge an exorbitantly high price for a powerful new hepatitis C drug would spark public outrage, but they pursued the profit-driven strategy anyway, according to a Senate Finance Committee investigation report released Tuesday.
-
ITC's Deveshwar, 7 other Indians in Harvard Business Review's list of top 100 CEOs
Eight Indian CEOs have made it to the list of 100 global chief executives, compiled by Harvard Business Review (HBR), with ITC's Y C Deveshwar and late Subir Raha of ONGC finding a place in the top 20.
